Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 104

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 104
---
 effects will
be observed in human studies, that they will translate into clinically meaningful outcomes, or that regulators will view these results
as sufficient for approval.

<div align='center'>67</div>

Epidemiology and Market Size Estimates for Nano-Candesartan (Liposomal ARB) in Pancreatic Cancer

Global Revenue Potential for Nano-Candesartan in Pancreatic Cancer

U.S. incidence of Pancreatic Cancer is estimated
at ~61,000 new cases per year. [4] Global incidence is estimated at ~495,000 cases annually. [5]

Revenue assumptions (U.S. Market Only):

| - | Per Patient Per                                            
 Month (PPPM) cost of treatment: estimated at $3,700–$7,400 |

| - | Assumed average duration of treatment           
 course (based on 3–4 months of use): 3.5 months |

| - | Per-patient course cost: $12,950                                                            
 downside case scenario – $25,900 upside case scenario. Downside case scenario here          
 reflects pricing at the lower end of the estimated range, driven by reimbursement pressure, 
 competition, or a shorter treatment course. Upside case scenario reflects pricing at the    
 upper end of the estimated range, aligned with premium pricing observed for other liposomal 
 oncology agents demonstrating significant clinical benefit, or a longer treatment course.   
 Final treatment duration will depend on outcomes from future clinical trials.               |

U.S. TAM based on the estimated 61,000 patients/year may then translate
to:

~$790 million to $1.58 billion/year downside and upside case scenario
respectively.

Global Revenue Potential for Nano-Candesartan in Pancreatic Cancer

Global TAM assumed at roughly 4 times the size of the U.S. market
at around $690 million:

| - | ~$3.2 billion in downside case scenario |

| - | ~$6.3 billion in upside case scenario |

Serviceable Obtainable Market (SOM) for Nano-Candesartan in Pancreatic Cancer

At an assumed ~50% market penetration, projected
U.S. revenue could reach approximately $390–790 million annually under the downside and upside case scenarios. This reflects the
premium pricing typical of targeted liposomal oncology therapeutics, the severity of pancreatic cancer, U.S. payer willingness to reimburse
high-cost treatments, and the lack of effective alternatives.

At assumed ~20% market penetration, projected
global revenue